PARP1 and breast carcinoma: Our current findings reveal that the enzymatic activity of PRMT6 and PARP1 is crucial in different links of transcriptional repressions, thus, for breast cancer cells with upregulated PRMT6 expression, administration of combined PRMT6 and PARP1 inhibitors may obstruct tumor progression by recovering the natural circadian rhythm.